Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:1380 |
| Name | endometrial cancer |
| Definition | A uterine cancer that is located_in tissues lining the uterus. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:5654 |
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
| NCT01379534 | Phase II | Dovitinib | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | Completed | USA | NZL | ITA | GBR | ESP | BRA | 1 |
| NCT01697566 | Phase III | Metformin | An Endometrial Cancer Chemoprevention Study of Metformin | Completed | USA | 0 |
| NCT01797523 | Phase II | Letrozole Everolimus Metformin | RAD/Letrozole/Metformin | Active, not recruiting | USA | 0 |
| NCT01874353 | Phase III | Olaparib | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Active, not recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 4 |
| NCT01935934 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | Completed | USA | CAN | 0 |
| NCT02035787 | Phase I | Metformin | Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients | Completed | USA | 0 |
| NCT02042495 | Phase II | Metformin | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | Withdrawn | CAN | 0 |
| NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
| NCT02269293 | Phase I | Carboplatin + Paclitaxel + Selinexor | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | Completed | USA | 0 |
| NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | DNK | 0 |
| NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
| NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | NOR | ESP | 0 |
| NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
| NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Unknown status | USA | ITA | GBR | ESP | 2 |
| NCT02606305 | Phase I | Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | Completed | USA | ESP | CAN | BEL | 0 |
| NCT02630823 | Phase I | Carboplatin + Paclitaxel + Pembrolizumab | MK-3475 Immunotherapy in Endometrial Carcinoma | Completed | USA | 0 |
| NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
| NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
| NCT02657928 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | Completed | USA | 0 |
| NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
| NCT02684227 | Phase II | Carboplatin + Enzalutamide + Paclitaxel | Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer | Completed | USA | 0 |
| NCT02715284 | Phase I | Dostarlimab-gxly | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DNK | CZE | CAN | BRA | ARG | 2 |
| NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
| NCT02728258 | Phase II | Copanlisib | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | Completed | USA | 0 |
| NCT02728830 | Phase I | Pembrolizumab | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | Completed | USA | 0 |
| NCT02788708 | Phase I | Lenvatinib + Paclitaxel | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | Completed | USA | 0 |
| NCT02899793 | Phase II | Pembrolizumab | Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | Completed | USA | 0 |
| NCT02912572 | Phase II | Avelumab + Talazoparib Avelumab Avelumab + Axitinib | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
| NCT02996825 | Phase I | Gemcitabine + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | Completed | USA | 0 |
| NCT03016338 | Phase II | Niraparib | Study of Niraparib in Recurrent Endometrial Cancer | Active, not recruiting | CAN | 0 |
| NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
| NCT03099499 | Phase II | Dordaviprone | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | Terminated | USA | 0 |
| NCT03120624 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03126110 | Phase Ib/II | INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | ESP | BEL | AUS | 0 |
| NCT03162627 | Phase I | Olaparib + Selumetinib | Selumetinib and Olaparib in Solid Tumors | Active, not recruiting | USA | 0 |
| NCT03188965 | Phase I | Elimusertib | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CHE | CAN | 3 |
| NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
| NCT03300557 | Phase II | Exemestane | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer | Completed | USA | 0 |
| NCT03310567 | Phase II | Epacadostat + Pembrolizumab | A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma | Withdrawn | USA | 0 |
| NCT03339843 | Phase II | Abemaciclib | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) | Completed | FRA | BEL | 0 |
| NCT03394027 | Phase II | Dordaviprone | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | Completed | USA | 0 |
| NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | GBR | FRA | ESP | 0 |
| NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab Ciforadenant + CPI-006 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
| NCT03474640 | Phase I | Toripalimab-tpzi | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Completed | USA | 0 |
| NCT03485729 | Phase II | Dordaviprone | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Terminated | USA | 0 |
| NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Completed | USA | 0 |
| NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
| NCT03552471 | Phase I | Mirvetuximab Soravtansine + Rucaparib | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Completed | USA | 0 |
| NCT03555422 | Phase III | Selinexor | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) | Active, not recruiting | USA | ITA | ISR | GRC | ESP | DEU | CZE | CAN | BEL | 1 |
| NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
| NCT03572478 | Phase Ib/II | Nivolumab + Rucaparib Nivolumab Rucaparib | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Terminated | USA | 0 |
| NCT03617679 | Phase I | Rucaparib | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
| NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
| NCT03643510 | Phase II | Abemaciclib + Fulvestrant | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
| NCT03671811 | Phase II | Megestrol acetate + Pterostilbene Megestrol acetate | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | Active, not recruiting | USA | 0 |
| NCT03675893 | Phase II | Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 Abemaciclib + Gedatolisib + Letrozole Abemaciclib + Letrozole + Zotatifin | RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer | Recruiting | USA | 0 |
| NCT03745950 | Phase II | Olaparib | UTOLA: UTerin OLAparib (UTOLA) | Completed | FRA | 0 |
| NCT03746431 | Phase Ib/II | 225Ac-FPI-1434 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Active, not recruiting | USA | CAN | AUS | 0 |
| NCT03748186 | Phase I | Luveltamab Tazevibulin | Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Completed | USA | ESP | 0 |
| NCT03835819 | Phase II | Mirvetuximab Soravtansine + Pembrolizumab | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | Active, not recruiting | USA | 0 |
| NCT03905148 | Phase Ib/II | Lifirafenib + Mirdametinib | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | Active, not recruiting | USA | AUS | 0 |
| NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Terminated | USA | FRA | BEL | AUS | 1 |
| NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | AUS | 2 |
| NCT03968406 | Phase I | Talazoparib | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Recruiting | USA | 0 |
| NCT03981796 | Phase III | Carboplatin + Paclitaxel Carboplatin + Dostarlimab-gxly + Paclitaxel | A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY) | Active, not recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BEL | 2 |
| NCT03983954 | Phase I | Durvalumab + Naptumomab estafenatox Durvalumab + Naptumomab estafenatox + Obinutuzumab | Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | Active, not recruiting | ISR | 1 |
| NCT04008797 | Phase I | Lenvatinib E7386 + Lenvatinib | A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | Recruiting | USA | ITA | FRA | ESP | DNK | CAN | 4 |
| NCT04044859 | Phase I | afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Active, not recruiting | USA | ESP | CAN | 0 |
| NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
| NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
| NCT04149691 | Phase I | CPL304110 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Recruiting | POL | 0 |
| NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Terminated | USA | SVK | AUS | 2 |
| NCT04157985 | Phase III | Nivolumab Ipilimumab Cemiplimab Pembrolizumab Atezolizumab | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Active, not recruiting | FRA | 0 |
| NCT04188548 | Phase I | Abemaciclib + Imlunestrant Imlunestrant Abemaciclib + Imlunestrant + Trastuzumab Abemaciclib + Anastrozole + Imlunestrant Abemaciclib + Exemestane + Imlunestrant Alpelisib + Imlunestrant Everolimus + Imlunestrant Abemaciclib + Imlunestrant + Letrozole | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) | Active, not recruiting | USA | FRA | ESP | BEL | AUS | 3 |
| NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Recruiting | USA | 0 |
| NCT04197219 | Phase II | Axitinib + Pembrolizumab | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Withdrawn | 0 | |
| NCT04214067 | Phase III | Pembrolizumab | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | Active, not recruiting | USA | 1 |
| NCT04300556 | Phase Ib/II | Dexamethasone + MORAb-202 MORAb-202 + Prednisolone MORAb-202 + Prednisone Lenvatinib + MORAb-202 MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRalph)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | GBR | FRA | ESP | 1 |
| NCT04319757 | Phase I | ACE1702 + Cyclophosphamide + Fludarabine | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | Completed | USA | 1 |
| NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Active, not recruiting | USA | 0 |
| NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
| NCT04463771 | Phase II | Pemigatinib + Retifanlimab Epacadostat + Retifanlimab Retifanlimab | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204) | Active, not recruiting | USA | ITA | GRC | FRA | DEU | BEL | 1 |
| NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | POL | NLD | ITA | GBR | ESP | CZE | CAN | BRA | BEL | AUS | 6 |
| NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT04498520 | Phase I | Abexinostat + Fulvestrant + Palbociclib | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | Withdrawn | 0 | |
| NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 1 |
| NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Completed | USA | 0 |
| NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
| NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
| NCT04641871 | Phase I | Sym021 + Sym023 Sym021 + Sym022 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | FRA | ESP | CAN | 0 |
| NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 + Irinotecan ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
| NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
| NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
| NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
| NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Terminated | USA | 0 |
| NCT04774419 | Phase II | Dostarlimab-gxly | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | Recruiting | USA | 0 |
| NCT04781088 | Phase II | Lenvatinib + Paclitaxel + Pembrolizumab | Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
| NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ISR | ESP | 0 |
| NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |
| NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Completed | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
| NCT05039801 | Phase I | Capivasertib + IACS-6274 Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
| NCT05057013 | Phase Ib/II | HMBD-001 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Active, not recruiting | GBR | 0 |
| NCT05067972 | Phase I | PF-07260437 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) | Terminated | USA | 1 |
| NCT05082025 | Phase II | Copanlisib + Fulvestrant | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | Active, not recruiting | USA | 0 |
| NCT05092373 | Phase I | Cabozantinib Atezolizumab + Nab-paclitaxel | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Recruiting | USA | 0 |
| NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
| NCT05112601 | Phase II | Ipilimumab + Nivolumab Nivolumab | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Recruiting | USA | 0 |
| NCT05117476 | Phase I | CLN-619 Carboplatin + CLN-619 + Paclitaxel + Pemetrexed Disodium CLN-619 + Pembrolizumab CLN-619 + Datopotamab deruxtecan | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MICA) | Active, not recruiting | USA | POL | ESP | AUS | 0 |
| NCT05123482 | Phase Ib/II | AZD2936 + AZD8205 AZD2936 + AZD8205 + Saruparib AZD8205 AZD8205 + Saruparib AZD8205 + AZD9574 AZD2936 + AZD8205 + AZD9574 | A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies | Recruiting | USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS | 5 |
| NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT05229900 | Phase I | SGN-ALPV | A Study of SGN-ALPV in Advanced Solid Tumors | Terminated | USA | SWE | GBR | ESP | CAN | 0 |
| NCT05252416 | Phase Ib/II | BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant | (VELA) Study of BLU-222 in Advanced Solid Tumors | Terminated | USA | ITA | GBR | 0 |
| NCT05262530 | Phase Ib/II | BNT142 | Safety and Preliminary Efficacy Trial of BNT142 in Patients with CLDN6-positive Solid Tumors | Active, not recruiting | USA | GBR | ESP | 1 |
| NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Unknown status | AUS | 1 |
| NCT05263492 | Phase II | Lenvatinib + Pembrolizumab | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | Terminated | USA | 0 |
| NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |
| NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
| NCT05317078 | Phase I | AMG 794 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Terminated | USA | CHE | AUS | 0 |
| NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
| NCT05417594 | Phase Ib/II | AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | SWE | GBR | ESP | DEU | AUS | 1 |
| NCT05419817 | Phase II | Pembrolizumab + Sitravatinib | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | Withdrawn | 0 | |
| NCT05438329 | Phase Ib/II | DB-1305 BNT327 + DB-1305 DB-1305 + Pembrolizumab | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |
| NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Terminated | USA | AUS | 0 |
| NCT05523440 | Phase II | Bevacizumab + Niraparib Niraparib | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | Terminated | USA | 0 |
| NCT05527184 | Phase I | IMGN151 | First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Recruiting | USA | NLD | ITA | IRL | FRA | ESP | DEU | CAN | BEL | AUS | 0 |
| NCT05548296 | Phase Ib/II | Prexasertib Gemcitabine + Prexasertib | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Recruiting | USA | 0 |
| NCT05554328 | Phase II | Selumetinib Olaparib + Selumetinib | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Recruiting | USA | 1 |
| NCT05572684 | Phase Ib/II | NC410 + Pembrolizumab | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
| NCT05579366 | Phase Ib/II | Carboplatin + PRO1184 PRO1184 Bevacizumab + PRO1184 Pembrolizumab + PRO1184 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/PRO1184-001) (RAINFOL-01) | Recruiting | USA | 1 |
| NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-3500 + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Active, not recruiting | CAN | 0 |
| NCT05634499 | Phase II | Giredestrant | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (EndomERA) | Active, not recruiting | USA | POL | ITA | CAN | 0 |
| NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
| NCT05650203 | Phase I | JS006 + JS009 + Toripalimab-tpzi JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 | |
| NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
| NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Withdrawn | USA | 0 |
| NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors | Recruiting | USA | ESP | 0 |
| NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05691504 | Phase I | APG-1252 + Cobimetinib | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | Recruiting | USA | 0 |
| NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Active, not recruiting | USA | ESP | BEL | 0 |
| NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
| NCT05761951 | Phase II | DKN-01 + Pembrolizumab | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT05768139 | Phase Ib/II | Exemestane + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Anastrozole + Ribociclib + STX-478 Anastrozole + Palbociclib + STX-478 Letrozole + Ribociclib + STX-478 Letrozole + Palbociclib + STX-478 Fulvestrant + Ribociclib + STX-478 Fulvestrant + Palbociclib + STX-478 Fulvestrant + STX-478 STX-478 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1) | Recruiting | USA | NLD | ITA | IRL | FRA | ESP | DEU | BEL | 1 |
| NCT05797831 | Phase II | KRT-232 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Recruiting | USA | SWE | SVN | ROU | POL | NOR | LTU | ITA | ISR | HUN | FIN | EST | ESP | DNK | CAN | AUT | 1 |
| NCT05798611 | Phase II | ART0380 | Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) | Terminated | USA | FRA | ESP | 0 |
| NCT05819892 | Phase I | Cisplatin + Dostarlimab-gxly + Paclitaxel Carboplatin + Dostarlimab-gxly + Paclitaxel | Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | Recruiting | USA | 0 |
| NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
| NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Unknown status | USA | 0 |
| NCT06036836 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Active, not recruiting | USA | TUR | NLD | ITA | FRA | DEU | CAN | AUS | 2 |
| NCT06040970 | Phase Ib/II | Cisplatin + Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | Recruiting | USA | 0 |
| NCT06120283 | Phase I | BGB-43395 BGB-43395 + Elacestrant BGB-43395 + Letrozole BGB-43395 + Fulvestrant | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Recruiting | USA | NZL | FRA | BRA | AUS | 6 |
| NCT06129604 | Phase II | TPST-1495 | Pilot Window of Opportunity Trial (POET) | Recruiting | USA | 0 |
| NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
| NCT06180733 | Phase II | Pembrolizumab | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II) | Recruiting | NLD | 0 |
| NCT06218914 | Phase I | AZD0240 NT-112 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | AUS | 0 |
| NCT06253494 | Phase Ib/II | HER2 Vaccine + Lenvatinib + Nogapendekin alfa inbakicept + Pembrolizumab HER2 Vaccine + Lenvatinib + Pembrolizumab | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | Recruiting | USA | 0 |
| NCT06257264 | Phase I | BG-68501 + Fulvestrant BG-68501 + BGB-43395 + Fulvestrant BG-68501 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Recruiting | USA | NZL | ISR | AUS | 3 |
| NCT06264921 | Phase I | NKT3447 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Terminated | USA | 0 |
| NCT06276491 | Phase I | XmAb541 | Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
| NCT06293898 | Phase I | BL-M07D1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Recruiting | USA | 0 |
| NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
| NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Withdrawn | ESP | 0 |
| NCT06340568 | Phase III | Paclitaxel Doxorubicin DB-1303 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer (Fern-EC-01) | Recruiting | GBR | CAN | AUS | 3 |
| NCT06400472 | Phase I | Bevacizumab + LY4170156 LY4170156 + Pembrolizumab Carboplatin + LY4170156 LY4170156 Itraconazole + LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
| NCT06466187 | Phase I | SGN-MesoC2 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
| NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
| NCT06515613 | Phase I | CTIM-76 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06518564 | Phase II | Avelumab + M1774 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | Recruiting | USA | 0 |
| NCT06533332 | Phase I | ERX-315 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | Recruiting | AUS | 0 |
| NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
| NCT06586957 | Phase I | NKT3964 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT06597721 | Phase I | AMT-754 | AMT-754 in Patients With Selected Advanced Solid Tumours | Recruiting | USA | AUS | 0 |
| NCT06620029 | Phase Ib/II | BMX-001 + Paclitaxel | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | Not yet recruiting | USA | 0 |
| NCT06680739 | Phase II | Durvalumab Durvalumab + Tremelimumab | Single cEll pRofiling PErsistaNce To ImmuNothErapy (SERPENTINE) | Recruiting | ESP | 0 |
| NCT06710847 | Phase Ib/II | GSK4418959 GSK4418959 + unspecified PD-1 antibody | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (SYLVER) | Recruiting | USA | AUS | 2 |
| NCT06712472 | Phase III | Olaparib | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer (RAINBO-RED) | Recruiting | FRA | 0 |
| NCT06714617 | Phase I | BL-M17D1 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
| NCT06738966 | Phase I | BL0175 | A Study of BL0175 Injection in Postmenopausal Female Adults with HR-positive, Locally Advanced or Metastatic Cancer | Recruiting | 1 | |
| NCT06752681 | Phase I | MTX-13 | To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
| NCT06754761 | Phase I | Ceralasertib | Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib | Not yet recruiting | GBR | 0 |
| NCT06760819 | Phase II | Sevabertinib | A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (panSOHO) | Recruiting | USA | ITA | FRA | ESP | DNK | CHE | CAN | AUS | 3 |
| NCT06771219 | Phase I | SLV-154 | SLV-154 Treatment of Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT06795009 | Phase I | XL092 Paclitaxel + XL092 | Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Recruiting | USA | 0 |
| NCT06796907 | Phase Ib/II | GSK5733584 Bevacizumab + GSK5733584 Dostarlimab-gxly + GSK5733584 | A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | Recruiting | TUR | SWE | POL | NOR | NLD | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BEL | AUS | ARG | 3 |
| NCT06906341 | Phase II | Bevacizumab + Nab-paclitaxel + Relacorilant Nab-paclitaxel + Relacorilant | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Recruiting | USA | POL | ITA | FRA | ESP | DEU | BEL | 1 |
| NCT06925724 | Phase II | Ivonescimab | A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Recruiting | USA | 0 |
| NCT06943521 | Phase Ib/II | MT-4561 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT06959706 | Phase I | TGW101 + TRG001 | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06975293 | Phase Ib/II | STC-15 + Toripalimab-tpzi | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers | Recruiting | USA | 0 |
| NCT06999187 | Phase I | DR-0202 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Recruiting | USA | 0 |
| NCT07030712 | Phase I | MK-8294 | A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) | Recruiting | USA | NLD | ISR | 0 |
| NCT07046923 | Phase I | LY4175408 | A Study of LY4175408 in Participants With Advanced Cancer | Recruiting | USA | FRA | ESP | 2 |
| NCT07139977 | Phase II | Enfortumab vedotin-ejfv | Study of EV for Recurrent Endometrial Carcinoma (EV-4-EC) | Not yet recruiting | USA | 0 |
| NCT07163325 | Phase I | EP102 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | Recruiting | NLD | ESP | CZE | BEL | 0 |
| NCT07182149 | Phase I | NRM-823 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Recruiting | USA | 0 |
| NCT07192068 | Phase II | Zanidatamab | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. (AcSe HER2) | Active, not recruiting | FRA | 0 |
| NCT07227168 | Phase I | Pembrolizumab + STRO-004 STRO-004 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Recruiting | USA | 0 |